{
    "clinical_study": {
        "@rank": "168195", 
        "arm_group": {
            "arm_group_label": "Ozurdex implant", 
            "arm_group_type": "Other", 
            "description": "Intravitreal injection of Ozurdex implant"
        }, 
        "brief_summary": {
            "textblock": "To determine if Ozurdex implant can offer an effective treatment for macular edema\n      associated with retinal vein occlusion when treatment with intravitreal Avastin, Lucentis,\n      or Eylea have not demonstrated a significant response."
        }, 
        "brief_title": "Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Retinal Vein Occlusion (RVO)", 
            "Macular Edema"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema", 
                "Retinal Vein Occlusion"
            ]
        }, 
        "detailed_description": {
            "textblock": "To determine whether Ozurdex implant can offer an efficacious alternative for treatment of\n      macular edema in the setting of retinal vein occlusion when treatment with intravitreal\n      bevacizumab (Avastin),ranibizumab (Lucentis), and/or aflibercept (Eylea) have not\n      demonstrated significant response."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All patients with Retinal Vein Occlusion (RVO) with available initial imaging and\n        documented treatment failure with bevacizumab, ranibizumab, or aflibercept. Treatment\n        failure is defined as lack of anatomic improvement (persistent intraretinal cystic\n        changes/macular edema with central subfield thickness greater than 250 microns on\n        time-domain OCT or greater than 275 microns on spectral domain OCT) with lack of visual\n        improvement (less than 2 lines of visual gain by Snellen acuity), despite 3 to 6\n        intravitreal anti-VEGF treatments over the preceding 6 months.\n\n        Exclusion Criteria:\n\n          -  Co-existing or pre-existing macular degeneration, diabetic macular edema,  or other\n             confounding disease processes\n\n          -  Interval surgical intervention, such as cataract surgery, that may confound visual\n             outcomes.\n\n          -  Pregnancy\n\n          -  Coexisting conditions that would represent relative or absolute contraindications\n             usage of ozurdex implant, including:\n\n          -  Ocular or periocular infections (including viral disease of the cornea and\n             conjunctiva such as active epithelial herpes simplex keratitis, vaccinia, varicella,\n             mycobacterial infection, and fungal diseases)\n\n          -  Advanced glaucoma\n\n          -  Aphakic eyes with rupture or missing posterior lens capsule\n\n          -  Eyes with anterior chamber intraocular lens and missing posterior lens capsule\n\n          -  Patients with known hypersensitivity to components of this product"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946399", 
            "org_study_id": "Ozurdex RVO 2013"
        }, 
        "intervention": {
            "arm_group_label": "Ozurdex implant", 
            "description": "Intravitreal injection of Dexamethasone implant", 
            "intervention_name": "Ozurdex implant", 
            "intervention_type": "Drug", 
            "other_name": "Dexamethasone implant"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63128"
                }, 
                "name": "The Retina Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Dexamethasone Intravitreal Implant for Retinal Vein Occlusion Associated Macular Edema After Treatment Failure With Anti-VEGF Medications", 
        "overall_official": {
            "affiliation": "Retina Research Institute", 
            "last_name": "Gaurav K Shah, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Improvement in best-corrected Snellen visual acuity following initiation of Ozurdex therapy", 
            "safety_issue": "No", 
            "time_frame": "6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946399"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Retina Research Institute, LLC", 
            "investigator_full_name": "Rhonda Weeks", 
            "investigator_title": "Gaurav K. Shah, MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Anatomic/angiographic improvement in macular edema as evaluated by OCT and fluorescein angiography", 
            "safety_issue": "No", 
            "time_frame": "6 Months"
        }, 
        "source": "Retina Research Institute, LLC", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Retinal Consultants of Arizona", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Retina Vitreous Associates Medical Group", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "West Coast Retina", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Retina Research Institute, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}